<?xml version="1.0" encoding="UTF-8"?><feed xmlns="https://www.w3.org/2005/Atom" xml:lang="it"><title type="text">pillole.org</title><subtitle type="text">Pillole di medicina telematica info professionali mediche</subtitle><id>https://www.pillole.org/public/aspnuke/news.asp</id><link rel="alternate" type="application/xhtml+xml" href="https://www.pillole.org/"/><link rel="self" type="application/atom+xml" href="https://www.pillole.org/public/aspnuke/feedatom10multi.asp?channel=14"/><author><name>Pillole.org</name><uri>https://www.pillole.org</uri><email>info@pillole.org</email></author><rights>Copyright (c) 2005, Pillole.org</rights><updated>2026-05-14T00:00:00+01:00</updated><entry><title type="html">Anemia nel paziente con malattia renale cronica</title><summary type="html">Una sintesi per punti delle nuove linee guida KIDGO sull'anemia nella malattia renale cronica.</summary><category term="news" scheme="https://www.pillole.org/public/aspnuke/news.asp/" label="News" /><id>https://www.pillole.org/public/aspnuke/news.asp,2026-05-14:?id=8942</id><link href="https://www.pillole.org/public/aspnuke/news.asp?id=8942" /><link rel="alternate" href="https://www.pillole.org/public/aspnuke/news.asp?id=8942" type="application/xhtml+xml" hreflang="it" /><updated>2026-04-12T06:28:00+01:00</updated></entry><entry><title type="html">Quando la statistica incontra la fisiologia individuale</title><summary type="html">Esisitono critiche alla formula CKD-EPI per la stima della funzionalit&#224; renale?</summary><category term="news" scheme="https://www.pillole.org/public/aspnuke/news.asp/" label="News" /><id>https://www.pillole.org/public/aspnuke/news.asp,2026-05-14:?id=8982</id><link href="https://www.pillole.org/public/aspnuke/news.asp?id=8982" /><link rel="alternate" href="https://www.pillole.org/public/aspnuke/news.asp?id=8982" type="application/xhtml+xml" hreflang="it" /><updated>2026-03-17T07:40:00+01:00</updated></entry><entry><title type="html">Malattia renale cronica: raccomandazioni utili in medicina generale</title><summary type="html">Sono state pubblicate le linee guida sulla gestione della malattia renale cronica utili ai medici di cure primarie.
</summary><category term="news" scheme="https://www.pillole.org/public/aspnuke/news.asp/" label="News" /><id>https://www.pillole.org/public/aspnuke/news.asp,2026-05-14:?id=8916</id><link href="https://www.pillole.org/public/aspnuke/news.asp?id=8916" /><link rel="alternate" href="https://www.pillole.org/public/aspnuke/news.asp?id=8916" type="application/xhtml+xml" hreflang="it" /><updated>2026-03-08T06:28:00+01:00</updated></entry><entry><title type="html">Un aggiornamento sulla malattia renale cronica</title><summary type="html">Una sintesi delle recenti linee guida della KDIGO. 
</summary><category term="news" scheme="https://www.pillole.org/public/aspnuke/news.asp/" label="News" /><id>https://www.pillole.org/public/aspnuke/news.asp,2026-05-14:?id=8781</id><link href="https://www.pillole.org/public/aspnuke/news.asp?id=8781" /><link rel="alternate" href="https://www.pillole.org/public/aspnuke/news.asp?id=8781" type="application/xhtml+xml" hreflang="it" /><updated>2025-09-07T08:31:00+01:00</updated></entry><entry><title type="html">Metformina nella grave insufficienza renale</title><summary type="html">Uno studio osservazionale scozzese suggerisce che potrebbe essere giustificato continuare a usare la metformina in pazienti con diabete di tipo 2 e grave insufficienza renale.</summary><category term="news" scheme="https://www.pillole.org/public/aspnuke/news.asp/" label="News" /><id>https://www.pillole.org/public/aspnuke/news.asp,2026-05-14:?id=8668</id><link href="https://www.pillole.org/public/aspnuke/news.asp?id=8668" /><link rel="alternate" href="https://www.pillole.org/public/aspnuke/news.asp?id=8668" type="application/xhtml+xml" hreflang="it" /><updated>2025-05-25T06:28:00+01:00</updated></entry><entry><title type="html">Utilit&#224; degli SGLT-2 inibitori nelle nefropatie croniche</title><summary type="html">Secondo un aggiornamento recente delle linee guida gli SGLT-2 inibitori devono essere usati anche nei pazienti con nefropatie croniche indipendentemente dalla presenza o meno di diabete di tipo 2 o di scompenso cardiaco.
</summary><category term="news" scheme="https://www.pillole.org/public/aspnuke/news.asp/" label="News" /><id>https://www.pillole.org/public/aspnuke/news.asp,2026-05-14:?id=8627</id><link href="https://www.pillole.org/public/aspnuke/news.asp?id=8627" /><link rel="alternate" href="https://www.pillole.org/public/aspnuke/news.asp?id=8627" type="application/xhtml+xml" hreflang="it" /><updated>2025-03-23T06:28:00+01:00</updated></entry><entry><title type="html">Insufficienza renale acuta</title><summary type="html">Una breve messa a punto sulle cause e sulla terapia dell'insufficienza renale acuta.
</summary><category term="news" scheme="https://www.pillole.org/public/aspnuke/news.asp/" label="News" /><id>https://www.pillole.org/public/aspnuke/news.asp,2026-05-14:?id=8608</id><link href="https://www.pillole.org/public/aspnuke/news.asp?id=8608" /><link rel="alternate" href="https://www.pillole.org/public/aspnuke/news.asp?id=8608" type="application/xhtml+xml" hreflang="it" /><updated>2025-02-23T06:28:00+01:00</updated></entry><entry><title type="html">Stimolanti l'eritropoiesi per la prevenzione dell'insufficienza renale acuta</title><summary type="html">Sono efficaci gli stimolanti l'eritropoiesi per la prevenzione dell'insufficienza renale acuta nei pazienti a rischio?
</summary><category term="news" scheme="https://www.pillole.org/public/aspnuke/news.asp/" label="News" /><id>https://www.pillole.org/public/aspnuke/news.asp,2026-05-14:?id=8546</id><link href="https://www.pillole.org/public/aspnuke/news.asp?id=8546" /><link rel="alternate" href="https://www.pillole.org/public/aspnuke/news.asp?id=8546" type="application/xhtml+xml" hreflang="it" /><updated>2024-11-10T06:28:00+01:00</updated></entry><entry><title type="html">Aceinibitori e sartani nelle nefropatie croniche</title><summary type="html">Nei pazienti con nefropatia avanzata iniziare un aceinibitore o un sartano riduce il rischio di dover ricorrere alla terapia renale sostitutiva, ma non la mortalit&#224;.</summary><category term="news" scheme="https://www.pillole.org/public/aspnuke/news.asp/" label="News" /><id>https://www.pillole.org/public/aspnuke/news.asp,2026-05-14:?id=8482</id><link href="https://www.pillole.org/public/aspnuke/news.asp?id=8482" /><link rel="alternate" href="https://www.pillole.org/public/aspnuke/news.asp?id=8482" type="application/xhtml+xml" hreflang="it" /><updated>2024-09-19T06:28:00+01:00</updated></entry><entry><title type="html">Gliflozine nelle nefropatie croniche</title><summary type="html">Dapagliflozin ed empagliflozin sono nuovi farmaci che possono essere usati nel paziente con nefropatia cronica indipendentemente dalla presenza di diabete o scompenso cardiaco.
</summary><category term="news" scheme="https://www.pillole.org/public/aspnuke/news.asp/" label="News" /><id>https://www.pillole.org/public/aspnuke/news.asp,2026-05-14:?id=8232</id><link href="https://www.pillole.org/public/aspnuke/news.asp?id=8232" /><link rel="alternate" href="https://www.pillole.org/public/aspnuke/news.asp?id=8232" type="application/xhtml+xml" hreflang="it" /><updated>2023-11-26T06:28:00+01:00</updated></entry></feed>